title: Advances with microRNAs in Parkinson's disease research.
abstract: Parkinson's disease (PD) is the second-most common age-dependent neurodegenerative disorder and is caused by severe degeneration of dopaminergic neurons in the substantia nigra pars compacta. Unfortunately, current treatment only targets symptoms and involves dopamine replacement therapy, which does not counteract progressive degeneration. MicroRNAs (miRNAs) are a class of small RNA molecules implicated in post-transcriptional regulation of gene expression during development. Recent studies show that miRNAs are playing an important role in the pathophysiology of PD. miRNA-based therapy is a powerful tool with which to study gene function, investigate the mechanism of the disease, and validate drug targets. In this review, we focus on the recent advances of the use of miRNAs in the pathogenesis of PD.
authors.affiliation: Department of Neurology, Xinhua Hospital Affiliated with Shanghai JiaoTong University School of Medicine, Shanghai, People's Republic of China ; School of Pharmacy, Shanghai JiaoTong University, Shanghai, People's Republic of China.
authors.forename: Liuqing
authors.initials: L
authors.lastname: Ma
authors.forename: Liangming
authors.initials: L
authors.lastname: Wei
authors.forename: Fei
authors.initials: F
authors.lastname: Wu
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Hu
authors.forename: Zhenguo
authors.initials: Z
authors.lastname: Liu
authors.forename: Weien
authors.initials: W
authors.lastname: Yuan
mesh_terms: D000818:Animals; D004298:Dopamine / Q000378:metabolism; D015195:Drug Design; D005786:Gene Expression Regulation; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D035683:MicroRNAs; D004298:Dopamine
keywords: LRRK2; miRNA; miRNA-based therapy; pathophysiology; α-synuclein